Respiratory diseases are often accompanied byprolonged inflammation in the respiratory tract and symptoms such as prolonged cough, bad departing sputum, shortness of breath and respiratory failure, and sometimes seriously impair quality of life. Moreover, the detainees disease can lead to severe complications.
The main reason for the disease "nodoes not pass, "it is the poor airway clearance of mucus. Viscous, thick sputum, which are accompanied by broncho-pulmonary diseases, blocks the mobility of cilia on the mucosal surface. As a result, in the respiratory tract accumulate a large amount of sputum, cough is hard and often painful. Therefore, the main treatment strategy should be aimed at changing the biochemical composition of mucus and its removal from the airways. It acts as a mucolytic Lasolvan. The basis of the effectiveness of the drug are multiple mechanisms of action.
Lasolvan active substance - ambroxolhydrochloride - breaks the connection between mucopolysaccharides phlegm, stimulates serous cells of the mucous glands, increases the amount of mucous secretion and activates hydrolyzing enzymes. As a result, changing the biochemical characteristics of pathological mucus, it becomes less viscous, it is diluted. A more liquid mucus coughed much easier.
Also under the influence of stimulated Lasolvanproduction of surfactant - a protective substance that supports the alveoli in the "straightened" state. In this state, the alveoli are fully operational and exercise effective gas exchange. At the same time the drug activates the movement of the cilia of the epithelium, which accelerates the transport of mucus. This is a rapid and "physiological" removal of mucus from the respiratory tract. Speaking of Lasolvan mucolytic effect, it should be noted that it is the only drug in the group of drugs, which activates the ciliated epithelium of the bronchi.
But Lasolvan - is not only effectivemucolytic, it also has antioxidant, antiinflammatory and immunomodulatory properties. Mucosolvan relieves inflammation in respiratory tissues, inhibiting neutrophil chemotaxis, interleukin-1 production and histamine. Increased production of immunoglobulins (IgA, IgG) contributes to the activation of local immunity in the lungs and bronchi.
A significant advantage is the Lasolvanhis fruitful "cooperation" with antibiotics. Mucosolvan accelerates the passive diffusion of antibiotics through the blood-alveolar barrier and increases the bioavailability of antibiotics in the lung tissue. In clinical trials it was well established that the joint appointment Lasolvan antibiotics and recovery times are reduced.
It is also important that Lasolvan being originaldrug has been well studied and has a number of advantages compared with generics: biological protected, fewer adverse reactions, especially allergic. A number of works devoted to research Lasolvan noted that in its application the likelihood of complications from the gastrointestinal tract is much less than when using ambroxol generic. Therefore Lasolvan approved for use and peptic ulcer disease, and other serious diseases.
The use in therapy of bronchopulmonaryLasolvan diseases allows the patient to reduce the recovery time frame to pass a shorter course of antibiotic therapy, and to avoid the potential risks of side effects.